fda tirzepatide ruling Compounders lose battle over Eli Lilly weight loss drug and shortage list FDA approves diabetes drug tirzepatide

Uribe-Querol, E

Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists. Journal of Clinical Medicine

GLP-1 production increases feeling of satiety by: slowing gastric emptying feel fuller, faster & longer suppressing appetite receptors in brain less hunger & cravings GLP-1 cells in the small intestine regulate carbohydrate metabolism through: increasing insulin production regulates blood glucose suppressing glucagon release Ideal Candidates GLP-1 medications have been successfully used for obese patients (BMI greater than or equal to 30) and for overweight patients (BMI greater than or equal to 27) who also have other health conditions contributing to weight

Weight loss drugs are not on formulary so when approved through the PA/NF process they will default to the highest applicable tier cost share

The peak purity was estimated using two factors such as the purity factor and the threshold